Cargando…

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients

Background and Purpose: Tacrolimus (TAC) has been proven to be a rapid-acting, steroid-sparing agent for myasthenia gravis (MG) therapy. However, evidence related to the effectiveness of TAC alone is rare. Therefore, this study was performed to investigate the effect of TAC monotherapy in MG patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Zhirong, Li, Zunbo, Shen, Faxiu, Zhang, Xueping, Lei, Lin, Su, Shengyao, Lu, Yan, Di, Li, Wang, Min, Xu, Min, Da, Yuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652845/ https://www.ncbi.nlm.nih.gov/pubmed/33193063 http://dx.doi.org/10.3389/fneur.2020.594152

Ejemplares similares

Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
por: Fan, Zhirong, et al.
Publicado: (2023)

Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis
por: Su, Shengyao, et al.
Publicado: (2022)

VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis
por: Su, Shengyao, et al.
Publicado: (2021)

A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
por: Di, Li, et al.
Publicado: (2022)

Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis
por: Zheng, Yiming, et al.
Publicado: (2022)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

Myasthenia Gravis Coexisting With Primary Sjögren's Syndrome: Report of Three Cases and Literature Review
por: Li, Xia, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis
por: Kim, Yool-hee, et al.
Publicado: (2019)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus
por: Bi, Zhuajin, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

Altered gut microbiota and metabolites in untreated myasthenia gravis patients
por: Ding, Xiao-Jun, et al.
Publicado: (2023)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Delayed Respiratory Insufficiency and Extramuscular Abnormalities in Selenoprotein N-Related Myopathies
por: Zhang, Shu, et al.
Publicado: (2021)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

Myasthenia Gravis and Physical Exercise: A Novel Paradigm
por: O'Connor, Laura, et al.
Publicado: (2020)

Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
por: Camelo-Filho, Antonio E., et al.
Publicado: (2020)

Concentric Needle Jitter in 97 Myasthenia Gravis Patients
por: Kouyoumdjian, João Aris, et al.
Publicado: (2020)

Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis
por: Thomsen, Jan Lykke Scheel, et al.
Publicado: (2020)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ph3o99fcpaq3ih1fsv7a8mvtjk